HEALTH-RELATED QUALITY OF LIFE AND HEALTH STATE UTILITY VALUES IN MODERATE TO VERY SEVERE COPD: A SYSTEMATIC LITERATURE REVIEW
Author(s)
Immaculate F. Nevis, PhD1, Anne-Mary Lewis-Mikhael, PhD2, Alan Martin, MSc3, Chris Raspin, MS3, Koyo Usuba, MSc4, Shibing Yang, PhD5.
1ICON, Fort Johnson, NY, USA, 2ICON, Mississauga, ON, Canada, 3GSK, London, United Kingdom, 4GSK, Mississauga, ON, Canada, 5GSK, Collegeville, PA, USA.
1ICON, Fort Johnson, NY, USA, 2ICON, Mississauga, ON, Canada, 3GSK, London, United Kingdom, 4GSK, Mississauga, ON, Canada, 5GSK, Collegeville, PA, USA.
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) significantly impacts patients' health-related quality of life (HRQoL). This systematic literature review (SLR) aimed to identify health state utility values (HSUVs), disutilities, and mapping algorithms for patients with moderate to very severe COPD and their caregivers.
METHODS: The SLR was conducted in accordance with PRISMA standards, with searches performed in MEDLINE, Embase, and CENTRAL databases, complemented by conference proceedings and additional sources on July 26, 2024. Studies were included based on predefined eligibility criteria, focusing on adult patients with moderate to very severe COPD and their caregivers. Data extraction and synthesis were performed using validated methods.
RESULTS: A total of 83 studies were included, comprising 79 primary studies and 4 mapping studies. Indirect methods, particularly the EuroQoL 5-Dimension 5-Level (EQ-5D) instrument, were primarily used to generate HSUVs in 87% of studies. Range of utilities for moderate to very severe COPD was from 0.25 to 0.86, with lower values associated with increased disease severity and history of exacerbation frequency. Mean utilities for exacerbations ranged from -0.120 (recorded within 3 days of hospital admission) to 0.65 (following an exacerbation), with worsening utilities following severe exacerbation (i.e., a COPD-related hospitalization). Caregiver utilities were reported in 3 studies, ranging from 0.76 to 0.88. Mapping studies developed algorithms to predict EQ-5D utilities from other HRQoL instruments, such as St George’s Respiratory Questionnaire and COPD Assessment Test.
CONCLUSIONS: This review highlights the significant impact of COPD disease severity and exacerbation frequency on HRQoL. The findings provide valuable HSUVs for economic modeling and emphasize the need for tailored interventions to improve HRQoL in patients with COPD and their caregivers. Funding: GSK (223395)
METHODS: The SLR was conducted in accordance with PRISMA standards, with searches performed in MEDLINE, Embase, and CENTRAL databases, complemented by conference proceedings and additional sources on July 26, 2024. Studies were included based on predefined eligibility criteria, focusing on adult patients with moderate to very severe COPD and their caregivers. Data extraction and synthesis were performed using validated methods.
RESULTS: A total of 83 studies were included, comprising 79 primary studies and 4 mapping studies. Indirect methods, particularly the EuroQoL 5-Dimension 5-Level (EQ-5D) instrument, were primarily used to generate HSUVs in 87% of studies. Range of utilities for moderate to very severe COPD was from 0.25 to 0.86, with lower values associated with increased disease severity and history of exacerbation frequency. Mean utilities for exacerbations ranged from -0.120 (recorded within 3 days of hospital admission) to 0.65 (following an exacerbation), with worsening utilities following severe exacerbation (i.e., a COPD-related hospitalization). Caregiver utilities were reported in 3 studies, ranging from 0.76 to 0.88. Mapping studies developed algorithms to predict EQ-5D utilities from other HRQoL instruments, such as St George’s Respiratory Questionnaire and COPD Assessment Test.
CONCLUSIONS: This review highlights the significant impact of COPD disease severity and exacerbation frequency on HRQoL. The findings provide valuable HSUVs for economic modeling and emphasize the need for tailored interventions to improve HRQoL in patients with COPD and their caregivers. Funding: GSK (223395)
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO191
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)